Maximilian Boesch and Sieghart Sopper contributed equally to this work.
Vav3 is a guanine nucleotide exchange factor that regulates the activity of Rho/Rac family GTPases. In a study on ovarian cancer, we recently demonstrated pronounced prognostic and predictive value of Vav3.1, a specific truncation variant of the parental Vav3 gene. Here, we sought to investigate the role of Vav3.1 in the most prevalent gynecological tumor entity, endometrial cancer.
Vav3.1 transcript levels were determined in a large cohort of endometrial cancer patients using variant-specific PCR (n = 239), and non-malignant endometrial tissue served as control (n = 26). Expression levels of Vav3.1 were stratified according to established clinicopathological characteristics and correlated to long-term patient survival (average follow-up of > 7.5 years). Type 1 and type 2 cancers were separately investigated.
While Vav3.1 was markedly overexpressed in endometrial cancer tissue, we could not detect associations with clinical parameters related to prognosis, such as FIGO stage and tumor grade. Kaplan–Meier estimators of different measures of survival failed to show prognostic significance of Vav3.1 in endometrial cancer. Lack of prognostic value was observed for both type 1 and type 2 cancers.
Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.
Boesch M et al (2014) The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem. Cell Char Oncotarget 5:7027–7039
Boesch M, Sopper S, Wolf D (2016a) Ionophore antibiotics as cancer stem cell-selective drugs: open questions. Oncologist. https://doi.org/10.1634/theoncologist.2016-0159PubMedPubMedCentral
Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Ludewig B, Wolf D (2016b) Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche biochimica. Et Biophysica Acta 1866:276–289. https://doi.org/10.1016/j.bbcan.2016.10.003
Boesch M, Reimer D, Sopper S, Wolf D, Zeimet AG (2018) (Iso-)form matters: differential implication of Vav3 variants in ovarian cancer oncologist. https://doi.org/10.1634/theoncologist.2017-0683
Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D, Chen J (2009) Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo molecular cancer research. MCR 7:615–623. https://doi.org/10.1158/1541-7786.MCR-08-0401CrossRefPubMed
Chan RW, Schwab KE, Gargett CE (2004) Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod 70:1738–1750. https://doi.org/10.1095/biolreprod.103.024109CrossRefPubMed
Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE (2009) Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 69:8241–8248. https://doi.org/10.1158/0008-5472.CAN-08-4808CrossRefPubMed
Kitchener HC, Trimble EL, Endometrial Cancer Working Group of the Gynecologic Cancer I (2009) Endometrial cancer state of the science meeting. Int J Gynecol Cancer 19:134–140. https://doi.org/10.1111/IGC.0b013e3181995f90CrossRefPubMed
Kusunoki S et al (2013) The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecologic Oncol 129:598–605. https://doi.org/10.1016/j.ygyno.2013.03.005CrossRef
Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH (2012) Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 72:3000–3009. https://doi.org/10.1158/0008-5472.CAN-11-2502CrossRefPubMed
Liu Y et al (2008) Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 68:6396–6406. https://doi.org/10.1158/0008-5472.CAN-08-0645CrossRefPubMedPubMedCentral
Masuda H, Maruyama T, Gargett CE, Miyazaki K, Matsuzaki Y, Okano H, Tanaka M (2015) Endometrial side population cells: potential adult stem/progenitor cells in endometrium. Biol Reprod 93:84. https://doi.org/10.1095/biolreprod.115.131490CrossRefPubMed
Partridge EE, Barnes MN (1999) Epithelial ovarian cancer: prevention, diagnosis, and treatment CA: a cancer. J Clin 49:297–320
Reimer D et al (2007) Clinical relevance of E2F family members in ovarian cancer—an evaluation in a training set of 77 patients. Clin Cancer Res 13:144–151. https://doi.org/10.1158/1078-0432.CCR-06-0780CrossRefPubMed
Rutella S et al (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15:4299–4311. https://doi.org/10.1158/1078-0432.CCR-08-1883CrossRefPubMed
Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice. Cancer Res 60:3605–3611 PubMed
van der Zee M et al (2015) IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126 + stem-like component and reduces tumor. Burden Cancer Res 75:3608–3622. https://doi.org/10.1158/0008-5472.CAN-14-2498CrossRefPubMed
Werner HM et al (2012) Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 125:103–108. https://doi.org/10.1016/j.ygyno.2011.11.008CrossRefPubMed
- Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Alain G. Zeimet
- Springer Berlin Heidelberg
- Journal of Cancer Research and Clinical Oncology
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
Neu im Fachgebiet Onkologie
Mail Icon II